Promising KRAS G12D data at #ESMO26!
QTX3034 + cetuximab: ORR 26%, DCR 79% (n=19).
Adding FOLFOX: 2/4 responses.
But what’s FOLFOX’s incremental benefit? Can dual KRAS/EGFR blockade deliver durable control without chemotherapy?
Early data—important questions.
126 浏览 · 2 赞 · 1 转发 · 0 回复
Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.org- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.org- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Targeted Oncology · x.com